| 34.6239 -0.098 (-0.28%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 41.2 | 1-year : | 41.75 |
| Resists | First : | 35.27 | Second : | 35.74 |
| Pivot price | 34.85  |
|||
| Supports | First : | 34.52 | Second : | 28.72 |
| MAs | MA(5) : | 34.72 |
MA(20) : | 34.98 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 23.7 |
D(3) : | 27.3  |
| RSI | RSI(14): 36.5 |
|||
| 52-week | High : | 36.24 | Low : | 34.52 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ EYEG ] has closed above bottom band by 25.0%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 34.74 - 34.92 | 34.92 - 35.06 |
| Low: | 34.24 - 34.43 | 34.43 - 34.57 |
| Close: | 34.42 - 34.74 | 34.74 - 34.98 |
EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. The company is headquartered in Waltham, Massachusetts and currently employs 11 full-time employees. The firm is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The firm's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The firm is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
Mon, 08 Nov 2021
EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company's Sharpened Clinical Development Strategy - GlobeNewswire
Tue, 26 Oct 2021
EyeGate Pharmaceuticals Appoints Eric J. Daniels, MD, MBA, as Chief Development Officer and Closes Acquisition of ... - Yahoo Finance
Tue, 24 Aug 2021
How Will the Market React to Eyegate Pharmaceuticals Inc (EYEG) Stock Getting a Neutral Rating - InvestorsObserver
Tue, 27 Jul 2021
EyeGate Skyrockets After It Names a New CEO and Plans for an Acquisition - TheStreet
Mon, 14 Jun 2021
EyeGate Pharma announces first patient dosed in phase 2 ocular surface inflammation study - Ophthalmology Times
Fri, 22 Nov 2019
Eyegate sees top-line corneal wound win as unlocking path to U.S. de novo filing - BioWorld Online
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|